Xofigo

Hopefully A Good Re-Start from Bayer Healthcare in Mending Their Ways & Building Trust with the Prostate Cancer Community

I want to share that I am hopeful that we have made progress with Bayer Healthcare and the issues I have written about surrounding the newly approved treatment for men with castrate resistant prostate cancer, Xofigo. I have shared that they failed to support the early access trials because of what they claimed were supply [...]

By Malecare|2017-10-19T10:49:48-04:00May 16th, 2013|Advanced Prostate Cancer, Alpharadin (radium-223), Drugs & Treatments, Early/Expanded Access Programs, General Information, Politics of Cancer, Uncategorized, Understanding APC, Xofigo|0 Comments

Ra 223 Dichloride (Xofigo®) Approved by the FDA

More great news for men with advanced prostate cancer that is castrate resistant and who also have symptomatic bone metastases and no known visceral metastatic disease. Today, Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) has approved (radium Ra 223 dichloride). Xofigo (zo-FEE-go) is the first and only alpha particle-emitting radioactive therapeutic [...]

By Malecare|2013-05-15T13:31:11-04:00May 15th, 2013|Advanced Prostate Cancer, Alpharadin (radium-223), FDA, General Information, Uncategorized, Understanding APC, Xofigo|2 Comments

Previous 56